O papel do gene TREML4 no desenvolvimento de lesões ateroscleróticas
Cardiovascular diseases (CVD) represent the highest percentage of morbidity and mortality in the world and its main cause is atherosclerosis. Atherosclerosis. is a multifactorial and inflammatory disease that has a long asymptomatic phase and commonly starts during childhood. Therefore, the accurate...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | doctoralThesis |
| Idioma: | pt_BR |
| Publicado em: |
Universidade Federal do Rio Grande do Norte
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/handle/123456789/46648 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| Resumo: | Cardiovascular diseases (CVD) represent the highest percentage of morbidity and
mortality in the world and its main cause is atherosclerosis. Atherosclerosis. is a
multifactorial and inflammatory disease that has a long asymptomatic phase and
commonly starts during childhood. Therefore, the accurate identification of
atherosclerosis. is the starting point for the implementation of effective strategies for the
primary prevention of CVD. TREML4 is a member of the immunoglobulin superfamily
expressed in different cell types of the immune system, such as monocytes and
macrophages and is related to CVD. We analyzed by qRT-PCR and genotyping the gene
expression and polymorphisms (rs2803495 and rs2803496) of TREML4 in patients with
Coronary Artery Disease (CAD) (n=137), Subclinical Atherosclerosis (340) and PostAcute Infarcted Left Ventricular Dysfunction of the Myocardium (AMI) (65). Subjects
carrying the minor alleles (G and C) have higher expression of TREML4 (OR 8.01, 95%
CI 3.78 - 16.99, p <0.001 and OR 10.42, 95% CI 4.76 - 22 .78, p<0.001, respectively).
Patients with major coronary artery lesions have greater expression of TREML4 than
individuals without or with low and intermediate lesions (p<0.005). No association was
observed between TREML4 expression and AS or LV dysfunction post-AMI (p>0.05).
Through the in silico approach, we identified the miRNAS: miR-181a-5p, miR-200b-3p,
miR-24-3p, miR-296-5p, miR-361-5p, miR-423-5p, miR-486- 3p and miR-708-5p
potentially associated with TREML4. Thus, our results confirm that genetic
polymorphisms influence TREML4 expression and that TREML4 expression is a potential
biomarker for key steps in the progression of atherosclerosis and is not related to events
prior to CAD and Acute Coronary Syndrome. Furthermore, we propose that 8 miRNAs
differentially expressed in patients with CAD may be associated with inflammatory
pathways potentially regulated by TREML4. |
|---|